RecruitingPhase 2NCT05926427

Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement

Sponsor

Ruijin Hospital

Enrollment

25 participants

Start Date

Aug 10, 2023

Study Type

INTERVENTIONAL

Conditions

CNS Lymphoma

Summary

This single-center, open, single-arm study aim to evaluate the efficacy and tolerability of a therapy introducing orelabrutinib on the basis of rituximab and chemotherapy in treating patients with relapsed or refractory B-cell lymphoma invloving central nervous system.

Eligibility

Min Age: 14 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study tests a combination of targeted drugs (orelabrutinib plus rituximab and chemotherapy) in people with a type of blood cancer called B-cell lymphoma that has returned or stopped responding to treatment and has spread to the brain or spinal cord. **You may be eligible if...** - You are between 14 and 80 years old - You have been diagnosed with CD20-positive B-cell lymphoma confirmed by biopsy - Your lymphoma has spread to the central nervous system (brain/spinal cord) and you have received prior treatment for it - Your blood counts and organ function meet specific thresholds - Your heart pumping function (ejection fraction) is at least 50% **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have active hepatitis B or C - You have an immune deficiency condition - You have significant heart failure or low heart pumping function - You have another active cancer besides lymphoma - You have a serious active infection Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.